AMBER Data Support Green Light For Janssen's Symtuza
Executive Summary
More Phase III data for Janssen's first once-daily single tablet containing four drugs for use against HIV Symtuza support its use in treatment-naïve patients; the product awaits US approval.
You may also be interested in...
J&J’s Symtuza Approved, But Commercial Outlook Uncertain
The first HIV single-tablet regimen anchored by a protease inhibitor, Symtuza’s prospects are challenged by competitors already on the market and treatment guidelines that prefer integrase inhibitor regimens.
Janssen's Darunavir-Based Single-Tablet Effective In Late-Stage Switching Study
Switching to a once-daily single tablet containing four constituents that is centered on Janssen's protease inhibitor darunavir was non-inferior to other combination therapies after 48 weeks of therapy, say researchers running the Phase III EMERALD study.
Nine Pivotal Studies To Look Out For In 2024
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are nine (plus a few extras) that have caught attention for one reason or another, e.g., for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.